1. Search Result
Search Result
Results for "

β+catenin

" in MedChemExpress (MCE) Product Catalog:

380

阻害剤およびアゴニスト

4

スクリーニングライブラリ

6

蛍光色素

9

生化学アッセイ試薬

27

ペプチド

2

MCE キット

1

阻害性抗体

72

天然物

6

組換えタンパク質

13

同位体標識化合物

16

抗体

2

オリゴヌクレオチド

Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-12238
    IWR-1
    60+ Cited Publications

    endo-IWR 1; IWR-1-endo

    Organoid Wnt Inflammation/Immunology Cancer
    IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
    IWR-1
  • HY-120697
    MSAB
    45+ Cited Publications

    Wnt β-catenin Cancer
    MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin and promotes its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells .
    MSAB
  • HY-101085
    SKL2001
    60+ Cited Publications

    Wnt β-catenin Cancer
    SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .
    SKL2001
  • HY-P10925

    FOG-001; I-66

    β-catenin Cancer
    Zolucatetide (FOG-001;I-66) is a potent β-catenin inhibitor with an IC50 of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer .
    Zolucatetide
  • HY-18988
    ETC-159
    5+ Cited Publications

    ETC-1922159

    Porcupine Wnt Cancer
    ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. ETC-159 inhibits β-catenin reporter activity with an IC50 of 2.9 nM.
    ETC-159
  • HY-N0101
    Neohesperidin
    5+ Cited Publications

    Hesperetin 7-O-neohesperidoside

    β-catenin Wnt Inflammation/Immunology
    Neohesperidin is a flavonoid compound abundant in citrus plants with antioxidant and anti-inflammatory effects. Neohesperidin can upregulate the Wnt/β-catenin signaling pathway, enhance the nuclear translocation of β-catenin and the differentiation of bone marrow stromal cells .
    Neohesperidin
  • HY-109103
    Tegatrabetan
    5 Publications Verification

    Tegavivint; BC2059

    β-catenin Cancer
    Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) .
    Tegatrabetan
  • HY-100760
    Toxoflavin
    5+ Cited Publications

    Xanthothricin; Toxoflavine; PKF-118-310

    β-catenin Bacterial Antibiotic Histone Demethylase Infection Cancer
    Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor and antibiotic activity .
    Toxoflavin
  • HY-N0060B
    (E)-Ferulic acid
    1 Publications Verification

    (E)-Coniferic acid

    β-catenin Bcl-2 Family Ferroptosis Endogenous Metabolite Cancer
    (E)-Ferulic acid is an isomer of ferulic acid, an aromatic compound abundant in plant cell walls. (E)-Ferulic acid causes phosphorylation of β-catenin (β-catenin), leading to proteasome degradation, increasing the expression of pro-apoptotic factor Bax and reducing pro-apoptotic factor Expression of the survival factor survivin. (E)-Ferulic acid can effectively remove reactive oxygen species (ROS) and inhibit lipid peroxidation. (E)-Ferulic acid exerts antiproliferative and antimigratory effects in the human lung cancer cell line H1299.
    (E)-Ferulic acid
  • HY-13815
    KY02111
    5 Publications Verification

    Wnt Cardiovascular Disease
    KY02111 is a canonical WNT signaling (β-catenin) inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .
    KY02111
  • HY-151520

    Wnt Cancer
    Wnt/β-catenin agonist 4 (Derivative 83) is an agonist of Wnt that activates Wnt/β-catenin signal transmission .
    Wnt/β-catenin agonist 4
  • HY-P5819
    xStAx-VHLL
    3 Publications Verification

    Wnt PROTACs β-catenin Cancer
    xStAx-VHLL is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .
    xStAx-VHLL
  • HY-122649

    β-catenin Cancer
    UU-T01 is a β-catenin inhibitor with a KD of 0.531 μM. UU-T01 binds to the K435, R469 and K508 residues of β-catenin, disrupting the β-catenin/TCF4 protein-protein interaction .
    UU-T01
  • HY-111760

    Molecular Glues β-catenin E1/E2/E3 Enzyme Cancer
    NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCF β-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM .
    NRX-252262
  • HY-B1057
    Nefopam hydrochloride
    3 Publications Verification

    Fenazoxine hydrochloride

    β-catenin Neurological Disease Cancer
    Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    Nefopam hydrochloride
  • HY-172920

    Wnt β-catenin EGFR ERK COX Akt GSK-3 c-Myc Apoptosis Interleukin Related JNK Inflammation/Immunology Cancer
    Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research .
    Wnt/β-catenin-IN-6
  • HY-111836

    Molecular Glues β-catenin Cancer
    NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation .
    NRX-252114
  • HY-141448
    NRX-2663
    1 Publications Verification

    β-catenin E1/E2/E3 Enzyme Cancer
    NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 μM and a Kd of 54.8 nM .
    NRX-2663
  • HY-102028
    KY1220
    3 Publications Verification

    Wnt β-catenin Cancer
    KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway, with an IC50 of 2.1 μM in HEK293 reporter cells .
    KY1220
  • HY-147007
    β-catenin-IN-3
    1 Publications Verification

    β-catenin Wnt CDK Cancer
    β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells .
    β-catenin-IN-3
  • HY-18959
    CWP232228
    5+ Cited Publications

    β-catenin Wnt Cancer
    CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .
    CWP232228
  • HY-138301
    Miclxin
    1 Publications Verification

    DS37262926

    Wnt β-catenin Apoptosis Cancer
    Miclxin (DS37262926) is a potent inhibitor of mutant β-catenin, involving in Wnt signaling pathway. Miclxin induces β-catenin-dependent apoptosis, leads to severe mitochondrial damage with the loss of mitochondrial membrane. Miclxin kills tumor via targeting to MIC60, a major components of the mitochondrial contact site and cristae organizing system (MICOS) complex .
    Miclxin
  • HY-161719
    NF764
    1 Publications Verification

    β-catenin Cancer
    NF764 is a potent β-catenin (CTNNB1) degrader. NF764 reduces CTNNB1 protein levels in a proteasome-dependent manner. NF764 can be used in the study of cancer .
    NF764
  • HY-144984

    β-catenin Molecular Glues Cancer
    NRX-1933 is a type of molecular glue. NRX-1933 is a β-catenin:β-TrCP interaction enhancer for the development of small molecule degraders. NRX-1933 promotes the ubiquitination of mutated β-Catenin, leading to degradation. NRX-1933 can be applied to tumor research on abnormal activation of Wnt/β - catenin signaling pathway .
    NRX-1933
  • HY-108442
    JW67
    1 Publications Verification

    Wnt Cancer
    JW67 inhibits the canonical Wnt signaling with an IC50 of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth .
    JW67
  • HY-136464
    β-catenin-IN-2
    3 Publications Verification

    β-catenin Cancer
    β-catenin-IN-2 (Compound H1B1) is a potent β-catenin inhibitor. β-catenin-IN-2 can be used for the study of colorectal cancer .
    β-catenin-IN-2
  • HY-148055

    Wnt β-catenin Cardiovascular Disease
    Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis .
    Wnt/β-catenin agonist 3
  • HY-141873
    Wnt/β-catenin agonist 2
    1 Publications Verification

    Wnt β-catenin Others
    Wnt/β-catenin agonist 2 is a potent Wnt agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction . (From patent WO2007078113A1, compound 39)
    Wnt/β-catenin agonist 2
  • HY-114321
    Wnt/β-catenin agonist 1
    5+ Cited Publications

    Wnt Cancer
    Wnt/β-catenin agonist 1 (compound 3f) is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM .
    Wnt/β-catenin agonist 1
  • HY-115539

    Wnt β-catenin Histone Acetyltransferase Cancer
    Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP .
    Windorphen
  • HY-112359

    β-catenin Wnt Cancer
    C-82 is a second-generation specific CBP/β-catenin antagonist, which inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300 .
    C-82
  • HY-P5819A
    xStAx-VHLL TFA
    3 Publications Verification

    PROTACs β-catenin Wnt Cancer
    xStAx-VHLL TFA is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .
    xStAx-VHLL TFA
  • HY-141450

    β-catenin Cancer
    NRX-103095 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 163 nM .
    NRX-103095
  • HY-141449

    Molecular Glues β-catenin Cancer
    NRX-103094 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM .
    NRX-103094
  • HY-112799

    Wnt β-catenin c-Myc CDK Survivin Cancer
    DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .
    DK419
  • HY-160709

    Wnt β-catenin Cancer
    Wnt/β-catenin-IN-2 (Compound 3235-0367) is a Wnt/β-catenin signaling pathway inhibitor, with IC50 and KD values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer .
    Wnt/β-catenin-IN-2
  • HY-119383

    Wnt β-catenin Cancer
    iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma .
    iCRT-5
  • HY-P10392B

    β-catenin Wnt Cancer
    aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
    aStAx-35R TFA
  • HY-163409

    Wnt β-catenin Inflammation/Immunology Cancer
    CKG012 is an inhibitor for Wnt/βcatenin signaling pathway. CGK012 inhibits release of HMGB1 and transcription of β-catenin, exhibits attenuating activities against cecal ligation and puncture (CLP)-induced sepsis and multiple myeloma cancer .
    CGK012
  • HY-119966

    Wnt β-catenin PPAR CDK Cancer
    CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .
    CCT036477
  • HY-P11112

    β-catenin Wnt Collagen Inflammation/Immunology
    PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing .
    PTD-DBM
  • HY-N0060BS

    (E)-Coniferic acid-d3

    β-catenin Bcl-2 Family Ferroptosis Endogenous Metabolite Cancer
    (E)-Ferulic acid-d3 is the deuterium labeled (E)-Ferulic acid. (E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls. (E)-Ferulic acid causes the phosphorylation of β-catenin, resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin. (E)-Ferulic acid shows a potent ability to remove reactive oxygen species (ROS) and inhibits lipid peroxidation. (E)-Ferulic acid exerts both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299 .
    (E)-Ferulic acid-d3
  • HY-160765

    APS-8-100-2

    Wnt Apoptosis Cancer
    WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation .
    WNTinib
  • HY-147651

    β-catenin CDK c-Myc Cancer
    β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a Ki of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .
    β-catenin-IN-4
  • HY-160488

    β-catenin Cancer
    PTK7/β-catenin-IN-1 (compound 01065) is a potent PTK7/β-catenin inhibitor with an IC50 of 8.9 μM and 56.5 μM for PTK7/β-catenin and p53/MDM2, respectively. PTK7/β-catenin-IN-1 has the potential for cancer research .
    PTK7/β-catenin-IN-1
  • HY-115543

    Wnt β-catenin Cancer
    β-catenin-IN-37 is a selective β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC50 values of 20 μM and 31 μM, respectively .
    β-catenin-IN-37
  • HY-173482

    Wnt β-catenin Cancer
    TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active TFAP4/Wnt/β-catenin inhibitor. TFAP4/Wnt/β-catenin-IN-1 has significant anticancer activity against a variety of cancer cells (such as gastric cancer, lung cancer, breast cancer, etc.), and has the strongest anticancer activity against MGC-803 gastric cancer cells (IC50: 3.92 μM). TFAP4/Wnt/β-catenin-IN-1 induces apoptosis and cell cycle arrest (S phase) in cancer cells by inhibiting the TFAP4/Wnt/β-catenin signaling pathway. TFAP4/Wnt/β-catenin-IN-1 can be used in the study of gastric cancer .
    TFAP4/Wnt/β-catenin-IN-1
  • HY-121118
    Coronaridine
    1 Publications Verification

    Wnt Neurological Disease Cancer
    Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression .
    Coronaridine
  • HY-179408

    β-catenin Apoptosis Cancer
    β-catenin-IN-9 is a β-catenin inhibitor. β-catenin-IN-9 induces apoptosis, cell cycle arrest, and inhibits migration, invasion, and epithelial-mesenchymal transition (EMT) in colorectal cancer cells. β-catenin-IN-9 suppresses the transcription of β-catenin and vimentin, and significantly inhibits β-catenin at the protein level. β-catenin-IN-9 can be used for the research of colorectal cancer .
    β-catenin-IN-9
  • HY-163768

    β-catenin Inflammation/Immunology Cancer
    Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with Kd of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
    Antitumor agent-172

オンラインお問い合わせ

入力情報は安全に管理されます. 必須入力項目.

タイトル

 

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

 

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: